Chronopharmacokinetics of doxorubicin in patients with breast cancer |
| |
| Authors: | P. Canal A. Sqalli M. de Forni C. Chevreau A. Pujol R. Bugat H. Roche J. Oustrin G. Houin |
| |
| Affiliation: | (1) Unités de Pharmacocinétique et de Pharmacologie Cliniques, Centre Claudius Regaud, France;(2) Unité de Pharmacocinétique, Hôpital Purpan, France;(3) Université Paul Sabatier, France;(4) Groupe de Chronobiologie et de Chronopharmacologie, Laboratoire de Biophysique et de Biomathématiques, Faculté de Pharmacie, France;(5) Centre Interdisciplinaire d'Etudes en Pharmacocinétique de Toulouse, Toulouse, France |
| |
| Abstract: | ![]()
Summary The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy, including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each patient at a four week interval.The total body clearance (CL) of DOX was significantly decreased when the drug was administered at 21.00 h, resulting in a longer elimination half-life and an increase in AUC. The renal clearance of DOX did not differ at the different times of administration, and it appears that the decrease in CL was related to a change in hepatic blood flow. The volume of distribution of the drug was not changed. |
| |
| Keywords: | Doxorubicin breast cancer chronopharmacokinetics total body clearance hepatic clearance hepatic blood flow |
| 本文献已被 SpringerLink 等数据库收录！ |
|
